
    
      The objective of the study is to describe the continuation of the human
      immunoglobulin-assisted recombinant human hyaluronidase (IGHy) therapy at 6 months from the
      start of treatment.

      The secondary objectives are to evaluate the quality of life of patients treated with human
      immunoglobulin-assisted recombinant human hyaluronidase (IGHy) therapy.
    
  